secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001140361-24-011766
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio prices $250M public offering at $29.00/share; funds acoramidis launch and pipeline
--------------------------------------------------------------------------------

- 8,620,690 shares priced at $29.00; underwriters have 30-day option for 1,293,103 additional shares.
- Net proceeds estimated at ~$250M; expected to fund operations into H2 2026.
- Proceeds to support commercial launch of acoramidis, if approved, and clinical/preclinical development.
- Offering expected to close March 8, 2024; 60-day lock-up for directors and officers.
- J.P. Morgan, Cantor Fitzgerald, Mizuho act as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/0001140361-24-011766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124011766/ny20019103x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-011766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer